LIGAND, DELOITTE TO PART COMPANY: Ligand Pharmaceuticals Inc., a developer and marketer of drugs to treat cancer, skin diseases and hormone-related diseases, said that Big Four firm Deloitte & Touche, its auditor of four years, will resign.

Last month, D&T told Ligand of its resignation plans effective upon the filing of Ligand’s 10-Q for the period ended June 30, 2004.

Register or login for access to this item and much more

All Accounting Today content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access